Tuesday, June 22, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

Expert Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Challenging Cases of HER2-Positive Breast Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Tuesday, June 22nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Ian E Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Inc, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seagen Inc.

Module 1: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer

  • Indications for and selection of neoadjuvant systemic therapy for patients with localized HER2-positive breast cancer
  • Key efficacy and safety results from the KATHERINE trial supporting the FDA approval of adjuvant T‑DM1 for patients with residual disease after neoadjuvant therapy
  • Clinical implications of the Phase II ATEMPT study comparing adjuvant T-DM1 to paclitaxel/trastuzumab for Stage I HER2-positive breast cancer; current nonresearch role, if any, of adjuvant T-DM1 for patients beyond those with residual disease after neoadjuvant therapy
  • Long-term efficacy and safety findings with pertuzumab as a component of adjuvant treatment for HER2-positive localized breast cancer; current role of pertuzumab
  • FDA approval of a fixed-dose subcutaneous formulation of pertuzumab, trastuzumab and hyaluronidase-zzxf; optimal integration into current clinical management
  • Final overall survival findings with neratinib as extended-adjuvant therapy; patient selection and clinical factors guiding use in practice
  • Ongoing and planned clinical trials investigating novel HER2-targeted strategies (eg, tucatinib, trastuzumab deruxtecan, margetuximab) for localized HER2-positive breast cancer; estimated study completion dates

Module 2: Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC)

  • Clinical factors in the selection and sequencing of therapy for patients with HER2-positive mBC
  • Available efficacy and safety data from the pivotal Phase II HER2CLIMB trial of tucatinib in combination with trastuzumab/capecitabine for HER2-positive mBC
  • Updated efficacy and safety results from the Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan for previously treated advanced HER2-positive breast cancer
  • Impact of neratinib/capecitabine on outcomes for patients with HER2-positive mBC with and without CNS disease in the Phase III NALA study
  • Biologic rationale for and mechanism of action of margetuximab; key efficacy and safety findings from the Phase III SOPHIA trial supporting the recent FDA approval of margetuximab in combination with chemotherapy for patients with HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 for metastatic disease
  • Recent FDA approvals of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan, neratinib/capecitabine and margetuximab/chemotherapy and integration into therapy for patients with and without brain metastases
  • Incidence, severity and optimal management of toxicities associated with recently approved anti- HER2 therapies

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Evaluate published research data in guiding the selection of therapy for patients with HER2-positive localized breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, including in patients with CNS metastases, incorporating current and recently approved anti-HER2 therapies.
  • Develop an understanding of the mechanisms of action of margetuximab, trastuzumab deruxtecan, tucatinib and neratinib and the clinical trial findings leading to the FDA approvals of these agents for previously treated, advanced HER2-positive breast cancer.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and develop supportive management strategies to prevent and ameliorate these toxicities for patients with HER2-positive breast cancer.
  • Appraise recent FDA approvals of and ongoing clinical research evaluating novel agents and treatment strategies for HER2-positive breast cancer, and counsel patients regarding protocol and nonresearch treatment recommendations.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr HamiltonAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Mersana Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Consulting Agreement: Flatiron Health; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ArQule Inc, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Hutchison MediPharma, Immunomedics Inc, InventisBio, Kadmon Corporation, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Mallinckrodt Pharmaceuticals, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, PharmaMar, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Stemcentrx, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TetraLogic Pharmaceuticals, Verastem Inc, Zymeworks; Travel/Accommodations/Expenses (payment or reimbursement of actual expenses): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genzyme Corporation, Guardant Health, Helsinn Healthcare SA, Heron Therapeutics, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sysmex Corporation, Tesaro, A GSK Company. Dr KropConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis. Dr O’ShaughnessyConsulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Oncology; Speakers Bureau: Lilly, Pfizer Inc, Seagen Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Inc, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seagen Inc.